|
Mitemcinal
|
DB06587 |
[Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.] |
|
KB001
|
DB05222 |
[KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.] |
|
Talviraline
|
DB07885 |
[Talviraline has been used in trials studying the treatment of HIV Infections.] |
|
rNAPc2
|
DB06552 |
[Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity. [A175642]] |
|
(R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)benzyl)guanidine
|
DB07887 |
|
|
Alisertib
|
DB05220 |
[Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.] |
|
3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLE-ACETIC ACID METHYL ESTER
|
DB07888 |
|
|
Bivatuzumab
|
DB06550 |
[Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]] |
|
(2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
|
DB07889 |
|
|
Beraprost
|
DB05229 |
[Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.] |
|
RDEA806
|
DB05228 |
[RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.] |
|
Lanimostim
|
DB06559 |
|
|
Tezosentan
|
DB06558 |
[Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.] |
|
APD791
|
DB05227 |
[APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.] |
|
2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID
|
DB07880 |
|
|
Lerdelimumab
|
DB06557 |
|
|
BTA9881
|
DB05226 |
[BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.] |
|
N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE
|
DB07881 |
|
|
Edifoligide
|
DB06556 |
|
|
AM103
|
DB05225 |
[AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Amira.] |
